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Because elective surgical repair of a large abdominal
aortic aneurysm (AAA) is standard treatment to avert the
risk of rupture, a proportion of patients has to be excluded
from treatment because of too high a risk associated with
major surgery.1,2 The establishment of endovascular AAA
repair (EAR) has changed the balance of risks and benefits
considerably.3 More patients with multiple comorbidities
can undergo treatment with the advent of EAR because
operative trauma, blood loss, and disturbance of circula-
tion and ventilation is minimal. There is ample evidence
that AAAs can now be successfully repaired in patients
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Objective: Endovascular abdominal aortic aneurysm repair (EAR) can be performed in patients whose conditions were pre-
viously considered unfit for conventional treatment of the aneurysm. However, because the life span in this category of
patients often is limited because of serious comorbidity, the efficacy of EAR in prolonging life expectancy remains uncertain.
This study involves the evaluation of preoperative risk classification and an assessment of the outcome of interventions.
Methods: The data of 3075 patients, who underwent operation in 101 European institutions that collaborated in the
EUROSTAR Registry, were assessed. Only the patients who had been prospectively enrolled in the registry were used
for this analysis. Patient characteristics, operative risk factors, procedural details, and types of devices were correlated
with preoperative estimates of operative risk, early and late mortality, complications, and primary and secondary out-
come success rates. In addition, the intermediate-term survival rates in patients with unfit conditions with EAR
(observed series) and with conservative approaches of the aneurysms (rupture rates as derived from the literature) were
compared in a mathematical model. 
Results: Of the overall study group, 2525 patients were at “normal” risk for a surgical procedure (group A), 399
patients had conditions that were considered unfit for open surgery (group B), and 151 patients had conditions that
were unfit for general anesthesia (group C). Both unfit categories had significantly more comorbid factors and larger
aneurysms than did the patients in good medical condition. Differences were observed in comorbidities between the
two high-risk categories, groups B and C. Factors that influenced the abdominal approach (previous laparotomies, hos-
tile abdomen, and obesity) and local anatomic factors (eg, retroperitoneal fibrosis, inflammatory aneurysm, dissections,
and enterostomy) were present in 19% of the patients with conditions that were unfit for open surgery and in only 1%
of the category unfit for anesthesia. In contrast, severe pulmonary disease was present in 33% of the patients with con-
ditions that were unfit for anesthesia as opposed to 11% of the patients with conditions that were unfit for open
surgery. The early and late mortality rates were significantly higher in the unfit categories (groups B and C). Life table
results showed a 3-year survival rate of 83% in patients at normal operative risk and of 68% in patients with unfit con-
ditions (P = .0001). An independent correlation with late death was shown for the clinical classification into high-risk
groups B and C, pulmonary disease, team experience of less than 60 procedures, and the diameter of the aneurysm. In
groups B and C, aneurysms smaller than 6.0 cm were associated with a 2-year survival rate of 80% and larger aneurysms
with a rate of 68% (P = .02). This difference was caused by an increased non–aneurysm-related mortality rate in the
group with aneurysms of more than 6 cm. The mathematical model showed an advantage of EAR with regard to the
reduction of the death rate in patients with unfit conditions as compared with no intervention after 1 year. The advan-
tage of EAR was observed in patients with AAAs between 5 and 6 cm and with larger aneurysms.
Conclusion: Early and late mortality rates were increased in patients with the preoperative clinical diagnosis “unfit for
open surgery and general anesthesia” as compared with patients at “normal” operative risk. EAR appeared of potential
benefit in patients with unfit conditions, regardless of the aneurysm diameter. The life expectancy of patients at high
risk who are considered for EAR should be longer than 1 year before any realistic gain in life span can be anticipated.
(J Vasc Surg 2002;35:211-21.)
whose conditions were previously considered unfit for
treatment.4-6 However, because the life span in this cate-
gory of patients often is limited because of serious comor-
bidities, the efficacy of EAR in prolonging life expectancy
remains uncertain.2 For the study of the mid-term out-
come of EAR in patients who would have been rejected by
their physicians for open repair, an analysis of the results
obtained in patients in this category enrolled in the
EUROSTAR database was performed. A preliminary
account of the results obtained in the high-risk groups in
the registry has previously been presented.7,8 This study
differs in several aspects from these previous communica-
tions. The study population consisted of prospectively
enrolled patients only, and the database has increased by
another 700 patients. We have assessed the various risk
factors taken into account for the definition of a patient
with unfit condition for open surgery or general anesthe-
sia. In addition, the outcome of the clinical estimate of
operative risks was compared with commonly used scored
indices. Comparison of the outcome in patients at high
risk and in patients at average risk who underwent EAR
was performed. The follow-up data of patients at high risk
with aneurysm who did not undergo operation, obtained
from the literature, were analyzed with a mathematical
model alongside the data of patients who underwent
EAR.
METHODS
Patients and organization of registry. Details on the
organization of the EUROSTAR Registry have been pub-
lished in previous articles.9,10 The objective of this registry
is the collection and analysis of data from patients with
endovascular treatment for AAA. The baseline data on
suitable patients are recorded in a standardized fashion by
participating institutions and are submitted for inclusion
to the EUROSTAR Data Registry Center. The findings at
follow-up examination, which involves clinical examina-
tion and computed tomographic (CT) scanning, are
recorded on data forms and are returned at regular inter-
vals to the Data Registry Center for processing and analy-
sis. The follow-up visits are at 1, 3, 6, 12, 18, and 24
months and annually thereafter. The reminders for over-
due follow-up data are regularly sent to the institutions
participating in the project. No outside monitoring of the
centers or a regular core laboratory for the evaluation of
CT scan studies are involved.
Excluded from this analysis were 454 patients whose
data had been enrolled retrospectively in the registry. Only
the patients with prospective enrollment, which was at
least 1 day before the EAR was performed, were included
in this study. This cohort consisted of 3075 patients who
underwent operation between June 1996 and March
2001. One hundred one centers were involved in patient
treatment and data procurement (Appendix shows list of
participating centers). The follow-up visits included a CT
scan examination, with contrast enhancement of the
abdominal blood vessels, in 94% of the patients and either
contrast angiography, magnetic resonance angiography, or
duplex scanning in the remainder of the patients.
Risk classifications, outcome events, and associated
variables. Preoperative risk factors and risk classifications as
recorded by the participating centers were used for correla-
tion with perioperative and late morbidity and mortality
rates. The American Society of Anesthesiology (ASA) physi-
cal status classification was used as a general risk indicator.11
The scoring system proposed by the Society of Vascular
Surgery and the International Society for Cardiovascular
Surgery—North American Chapter (SVS/ISCVS-NA) was
used to indicate more specific risk factors or the condition of
different systems.12 In addition to these specific risk cate-
gories, the physician’s prospective assessment of risk accord-
ing to one of the following broad categories was also taken
into account: normal medical condition (group A), condi-
tion that was unfit for an open surgical repair of the AAA
(group B), or condition that was unfit for general anesthesia
as needed for open AAA repair (group C). Patients with
unfit conditions for both open surgery and general anesthe-
sia were categorized in group C. The Case Record Form
allowed physicians to provide details in free text about the
reasons a patient was allocated to the two defined unfit cat-
egories (groups B and C). On the basis of this detailed infor-
mation, seven groups of factors that led to conditions being
categorized as unfit were defined retrospectively (Table I).
When a patient’s condition was diagnosed as both unfit for
open AAA repair and unfit for general anesthesia, the patient
was allocated to the latter category.
Univariate analysis for the examination of the relation-
ship between patient characteristics, aortoiliac morpho-
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Table I. Factors taken into account in categorization of unfit
1 Cardiovascular conditions (including cerebrovascular, status post heart transplant)
2 Pulmonary disorders
3 Combined cardiac and pulmonary diseases
4 Malignant diseases
5 Abdominal approach and local anatomic factors (eg, previous laparotomies, hostile abdomen, obesity, retroperitoneal fibrosis,
abdominal irradiation, inflammatory aneurysm, aortitis, dissections, enterostoma, bladder substitute, uretherostoma, skin 
infections, osteomyelitis of sternum, peritoneal dialysis, kidney transplant, status post liver transplant, pancreatitis)
6 Specified general disorders (eg, hemotologic rheumatoid arthritis, connective tissue disease, hemodialysis, chronic renal fail-
ure, peritoneal dialysis, liver disorders, neurologic disorders, muscle dystrophy, myasthenia, Parkinson’s disease, paraplegia, 
schizophrenia)
7 Poor condition: nonspecified general disorders (ASA 4, advanced age, multiple nonspecified comorbidity)
ASA, American Society of Anesthesiologists classification.
logic variables, and operative details with risk categories A,
B, and C was performed with χ2 test (for discrete vari-
ables) or with Mann-Whitney test (for continuous vari-
ables). The variables not obviously taken into account by
EUROSTAR participants for the designation of group B
or C were subjected to multivariate analysis for the delin-
eation of those factors that independently correlated with
these risk groups. Association between the most relevant
clinical variables and different outcome events was subse-
quently assessed with multivariate analysis. If subgroup
differences were statistically significant with the multivari-
ate analysis results, P value and odds ratio (OR) were cal-
culated. If outcome was an event that occurred during the
follow-up period, a Cox proportional hazards regression
model was used and the relative risk (RR) was calculated.
Cumulative rates of patient survival, freedom from rup-
ture, freedom from conversion, primary outcome success
(freedom from death, rupture, conversion, and secondary
intervention), secondary outcome success (freedom from
death, rupture, and conversion), and freedom from sys-
temic complications were estimated with life table analysis
for each study group. With regard to the latter, if more
than one systemic complication was experienced, the first
in time was considered for the life table analysis. A P value
of less than .05 was considered to represent a significant
difference for all the tests. Statistical analysis was per-
formed with SAS statistical software (version 6.12, SAS
Institute Inc, Cary, NC).
The observed cumulative survival rate in patients with
unfit conditions for open AAA repair or for general anes-
thesia who underwent EAR was compared with the
expected survival rate in a theoretically similar cohort of
patients without AAA treatment. It was intended to study
the effect of aneurysm rupture–related mortality in
untreated patients at high risk in addition to death from
other causes. This analysis involved mathematic modeling
of theoretic survival curves on the basis of the life table
data (number of patients, patient years of follow-up exam-
ination until death or rupture, and rate of death) of the
observed patients at high risk. An annual rupture rate of
11% for untreated patients with AAAs of 5 cm or more was
derived from a report by Reed et al.13 This rate was
observed by these investigators in patients with aneurysms
of 5 to 6 cm. Because the annual rupture rate for all
patients with a AAAs 5 cm or more was not provided, we
have applied the same rate in the mathematic model for
patients with aneurysms 5 cm or more and for patients
with aneurysms between 5 and 6 cm. In patients with
aneurysms 6 cm or more, we have used an annual rupture
rate of 26%, as reported by the same authors. We assumed
that all untreated patients who had aneurysm rupture
would have died from this rupture. A death rate was cal-
culated from the observed data, with the discarding of 1st
month deaths and the adding of deaths as the result of
aneurysm rupture. Because the observed survival rate
curve appeared approximately log linear, the survival rate
in the theoretic group was assumed to be of the negative
exponential type. The formula to describe such survival
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can be written as the exponential function: exp (–L × t), in
which t denotes follow-up time (in years) and L represents
the annual death rate.
RESULTS
Of the 3075 patients who constituted the study
cohort, 2525 were considered to be of normal operative
risk (group A), 399 had conditions that were indicated as
unfit for open surgical repair of the AAA (group B), and
151 had conditions that were unfit for the general anes-
thesia that would have been necessary for surgical repair
(group C). The mean follow-up period for the entire study
population was 13.0 months (range, 0 to 57 months).
The patients in group C were older than the patients
in group A. ASA classification of III or IV had a higher
prevalence in groups B and C as compared with group A.
This is in agreement with the expected greater operative
risk in patients classified in groups B and C. The individ-
ual systemic risk scores generally were higher in groups B
and C than in group A. With regard to abdominal
approach factors, previous laparotomies had been more
frequently performed in group B but not in group C
(Table II). Groups B and C had less favorable morpho-
logic and procedural factors in that the preoperative
aneurysm diameters were larger, the infrarenal neck was
more often angulated (only group C), adjunct procedures
were more frequently performed, and blocking of side
branches was more frequently needed. In addition, the
experience of the teams was limited to less than 60 proce-
dures in an appreciably larger proportion of cases in
Table II. Patient characteristics and comorbid factors
Group A Group B Group C
Mean age (years) 70.9 71.6 72.6*
Male gender 92.7 92.2 94
ASA physical status 3 or 4 48.8 81.8† 90.6†
SVS-ISCVS risk score
Diabetes‡ 9.9 13.5§ 15.9§
Smoking‡ 53 61.3* 67.0†
Hypertension‡ 60.6 67.2§ 61.5
Hyperlipemia‡ 38.9 41.7 51.1*
Cardiac‡ 56.9 75.3† 83.8†
Carotid‡ 14.9 22.5† 21.4§
Renal‡ 16.3 32.5† 27.8†
Pulmonary‡ 34.2 59.9† 76.2†
Ankle-brachial pressure index < 0.87 19.4 25.7§ 34.8†
Previous laparotomy 27 34.6* 26.5
Significant obesity 23.4 27.6 27.8
Figures represent percent of patients in each study group, unless stated
otherwise.
All P values determined with group A as a reference.
*P ≤ .01.
†P ≤ .001.
‡Risk score ≥ 1.
§P ≤ .05.
Group A, Patients at normal operative risk (n = 2525); Group B, patients
with conditions unfit for open abdominal aortic aneurysm repair (n = 399);
Group C, patients with conditions unfit for general anesthesia (n = 151);
ASA, American Society of Anesthesiologists classification; SVS-ISCVS,
Society of Vascular Surgery and the International Society for
Cardiovascular Surgery.
groups B and C. Straight or aortouniiliac devices were
more frequently used in the unfit categories. Local or
regional anesthesia was more frequently used in group C
than in group A or B (Table III). The different devices
used are represented in Table IV. There were no statistical
differences in the frequency of any device used in patients
at high risk.
Risk factors for patients with unfit conditions for
open surgery or anesthesia. The disorders that were
observed in groups B and C included significantly more
conditions that complicated the abdominal approach and
factors associated with adverse retroperitoneal anatomy in
group B (in 19%) and more pulmonary disorders in group
C (in 33%; Fig 1). Fig 1 also shows that there was a con-
siderable overlap in groups B and C in systemic and
abdominal approach/anatomic factors. For this reason,
these groups were combined as B/C in most of the fol-
lowing analyses.
Multivariate analysis was performed for the following
patient factors not obviously taken into account for desig-
nation of group B/C: age, gender, diabetes, current
smoking, obesity, and ankle-brachial blood pressure index.
Of these factors age, diabetes, obesity, and ankle-brachial
blood pressure index correlated with classification into
group B/C (Table V). 
Perioperative morbidity and mortality rates. In
533 patients (17.3%), an endoleak was observed on the
completion angiographic results. There were no differ-
ences in the overall prevalence of endoleaks nor in the
prevalence of individual types of endoleak between the
study groups. There were slightly more procedure-related
complications, such as problems in the advancement or
deployment of the device, iliac limb stenosis or occlusion,
and device migration, in groups B (10.3% of patients) and
C (11.3%) as compared with group A (7.1%; P = .02).
Cardiac complications during admission occurred more
frequently in group B (7.5%) and group C (9.9%) than in
group A (2.8%; P = .001). Overall, there were 52 patients
(1.7%) who needed conversion to an open procedure dur-
ing the primary operation or within the 1st month.
Conversions were needed in six patients (1.5%) in group
B, in two patients (1.3%) in group C, and in 44 patients
(1.7%) in group A, which represented a comparable preva-
lence in the study groups. Mortality rate during the 1st
month was higher in group B (19 patients; 4.8%) and in
group C (eight patients; 5.3%) than in group A (50
patients; 2.0%; both P = .001).
Multivariate analysis results, including preoperative
and operative variables and risk groups A, B, and C,
showed a significantly higher 1st-month mortality rate in:
1, patients in the combined risk groups B/C as compared
with group A (P = .039; OR, 1.8); 2, patients with ASA
classification of 3 or 4 (P = .03; OR, 1.9); 3, patients with
renal insufficiency (P = .0003; OR, 2.5); and 4, age of 70
years and more (P = .0004; OR, 3.0). Other variables,
such as a history of cardiac symptoms, pulmonary disor-
ders, diabetes, ankle-brachial index of less than 0.87, obe-
sity, and experience of the team did not correlate
significantly with operative mortality rate. 
Late morbidity and mortality rates. Nonfatal sys-
temic complications (cardiac, pulmonary, vascular, neuro-
logic, cancer, and other) occurred in 281 patients in the
whole series. The cumulative incidence rates of systemic
complications at 3 years in groups A and B/C were 19.4%
and 25.1%, respectively (P = .009). Conversions to an
open procedure, including procedures in the 1st month,
were needed in a total of 94 patients (81 in group A and
13 in group B/C), and rupture of the aneurysm occurred
in 20 patients (17 in group A and three in group B/C).
There were no statistically significant differences between
the study groups relating to the cumulative incidence rates
of these two events.
The prevalence of 1st month and late deaths com-
bined was 286 in the whole series and 83 in group B/C.
The causes of death in patients in group B/C were related
to cardiac disorders in 28 patients, malignant diseases in
10, stroke in seven, pulmonary disorders in eight, miscel-
laneous causes in 19, unknown causes in seven, and causes
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Table III. Variables representing aneurysm morphology device brands used and procedural details
Group A Group B Group C
Neck diameter (mean ± SD; mm) 22.9 ± 3.0 23.2 ± 3.2 23.3 ± 3.2
AAA diameter (mean ± SD; mm) 56.2 ± 10.6 58.3 ± 11.9* 59.5 ± 13.8*
Significant angulation of the infrarenal neck 22 25.3 31.8†
Configuration of device straight or aortouniiliac 5.9 9.3‡ 11.3*
Adjunct procedures 31.9 46.1* 44.4*
Team experience < 60 procedures 63.7 69.4† 81.5*
Endoleak present at completion of operation 17.1 18.0 19.2
Blocking of side branches 18.5 27.8* 31.8*
Regional/local anesthesia 23.6 28.1 64.8*
Figures represent percent of patients in each study group, unless stated otherwise.
All P values determined with group A as reference.
*P ≤ .001.
†P ≤ .05.
‡P ≤ .01.
Group A, Patients at normal operative risk (n = 2525); Group B, patients with conditions unfit for open abdominal aortic aneurysm repair (n = 399); Group
C, patients with conditions unfit for general anesthesia (n = 151); SD, standard deviation; AAA, abdominal aortic aneurysm.
related to the aneurysm in four. The 2-year cumulative
survival rate was significantly lower in group B (75.7%)
and group C (74.3%) than in group A (88.5%; P = .0001;
Fig 2). Aneurysms of 60 mm or larger were associated
with lower survival rates than were smaller aneurysms in
the study population as a whole. The group A and group
B/C 2-year survival rates for aneurysms 60 mm or more
and less than 60 mm in the entire cohort were 79.9% and
89.5%, respectively (P = .0001), in group A were 82.8%
and 91.0%, respectively (P = .0001), and in group B/C,
were 68.5% and 80.0% respectively (P = .023).
With the exclusion of the early deaths at multivariate
analysis, the following factors were found to be independ-
ently associated with late death: 1, the preoperative risk
classification in groups B and C (P = .001; RR, 1.8); 2,
pulmonary disorders (P = .005; RR, 1.6); 3, team experi-
ence of more than 60 procedures (P = .02; RR, 0.6); and
4, aneurysm diameter (P = .0002; RR, 1.8). 
The 2-year primary outcome success rates in groups A,
B, and C were 70.0%, 61.7%, and 59.0%, respectively (P =
.0001 for group A versus groups B and C). The secondary
outcome success rates in groups A, B, and C were 88.2%,
78.2%, and 79.9%, respectively (P = .0001 for group A
versus group B/C).
Comparison of patient survival rate with endovas-
cular abdominal aortic aneurysm repair and without
treatment of aneurysm (mathematical model). The
cumulative survival rate in patients with unfit conditions
who underwent EAR as observed in groups B and C com-
bined was compared with that of a hypothetically similar
group of patients at high risk who did not undergo treat-
ment with an estimated rate of rupture of aneurysms more
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than 5.0 cm on the basis of the outcome reported in the
literature. The mean period of follow-up in the 550
patients in group B/C was 9.8 months. Eighty-three
deaths were observed, including 27 patients who died
within the 1st month. With the exclusion of the latter 27
patients, the annual rate of deaths not related to the pro-
cedure was calculated to be 56 deaths per 449 person-
years (0.12). With the addition of an annual rupture rate
of 0.11 (derived from the report of Reed et al13) to this
figure, an overall theoretic annual death rate in the survival
formula of 0.12 + 0.11 = 0.23 is obtained. Fig 3 illustrates
observed overall survival rate in the group of 550 patients
and the theoretic survival rate curve on the basis of an
annual death rate of 0.23. From this figure, it appears that
in the early postoperative period avoidance of operative
mortality outweighs the advantage of a reduced rupture
rate in patients who undergo EAR. However, from 12
months after surgery, an increasing difference in survival
rate in favor of patients with EAR is observed. After 2
years, survival rate in the observed (EAR) group was 75%
and in the theoretic group was 63%.
When similar analyses were performed separately on
patients in group B/C with initial aneurysm diameters less
than 6.0 cm and 6.0 cm or more, the observed annual
death rates not related to the aneurysm were 0.11 and
0.15 per person-year, respectively. Intrapolated death-
from-rupture rates in the groups with aneurysms less than
6.0 cm and 6.0 cm or more in diameter were 0.11 and
0.26 per person-year, respectively.13 Observed cumulative
survival rate with EAR and theoretic survival rate without
EAR showed differences in favor of patients who under-
went EAR after 12 months of follow-up examination (Fig
Table IV. Device brands used in patients with normal operative risk and conditions unfit for open surgery
All Group A Group B/C
Device brand
Vanguard 910 758 (83.3%) 152 (16.7%)
AneuRx 794 653 (82.2%) 141 (17.8%)
Talent 525 426 (81.1%) 99 (18.9%)
Zenith 464 368 (79.3%) 96 (20.7%)
Excluder 216 178 (82.4%) 38 (17.6%)
EVT/Ancure 65 55 (84.6%) 10 (15.4%)
Other 101 87 (86.1%) 14 (13.9%)
Figures represent patient numbers. There were no statistical differences in proportions of any device brand used between groups A and B/C.
Device manufacturers are: Vanguard, Boston Scientific, Natick, Mass; AneuRx, Medtronic AVE, Cupertino, Calif; Talent, World Medical & Medtronic AVE,
Sunrise, Fla; Zenith, Cook, Bjaeverskov, Denmark; EVT & Ancure, Guidant, Menlo Park, Calif; Excluder, Gore, Flagstaff, Ariz.
Group A, Patients at normal operative risk (n = 2525); Group B/C, patients with conditions unfit for open repair or anesthesia (n = 550).
Table V. Results of multivariate analysis that correlated preoperative patient characteristics with high risk classification
(group B/C)
Coefficient SE Odds ratio P value
Age (years) 0.02 0.008 1.02 .048
Diabetes 0.46 0.18 1.58 .011
Obesity 0.29 0.14 1.34 .037
Ankle-brachial blood pressure index ≤0.87 0.49 0.14 1.64 .0005
SE, Standard error.
4). The advantage of EAR indicated by the proportional
death-from-rupture rate relative to the rate of death from
all causes at 2 years was comparable in patients with AAAs
less than 6.0 cm and 6.0 cm or more (44% and 43%,
respectively).
DISCUSSION
The proportion of patients for treatment of AAA who
will be turned down for surgical repair depends, in part,
on the type of practice attracted by some institutions. In
one regional referral practice, the proportion of patients
rejected for surgical AAA treatment was recently reported
as 30%, which indicates the importance of the problem.14
Endovascular repair of AAAs is applicable in patients at
high risk of complications associated with conventional
surgery. Several series that have been published in the
recent years suggest that technical success can be obtained
in those patients with unfit conditions for open aneurysm
repair at low risk of mortality and morbidity.4-6,15-17
However, one must question to what extent the benefit of
aneurysm rupture prevention is undermined by a high
incidence rate of non–aneurysm-related deaths, perhaps
resulting in a mid-term survival rate not appreciably dif-
ferent to that if the patients had not undergone treat-
ment.2,18 Direct comparison of patients at high risk who
underwent EAR or without any intervention has not been
performed previously.
In this study, patients with conditions considered unfit
for open aneurysm repair were identified from a large reg-
istry that consisted of more than 3000 prospectively
enrolled patients. In addition to ASA classification and the
SVS/ISCVS-NA system-based scoring schedule, a clinical
assessment was recorded in detail for all enrolled patients.
A distinction was made between patients with conditions
unfit for conventional aneurysm repair (group B) and
those patients with conditions unfit for prolonged general
anesthesia (group C). Pulmonary disorders were more fre-
quently associated with a diagnosis of unfit for general
anesthesia, and factors regarding laparotomy and intraab-
dominal anatomic factors had a higher prevalence in
patients with conditions considered unfit for open surgery.
However, analysis results of the other reasons for classifi-
cation as unfit showed a considerable overlap of comorbid
medical conditions in these two categories. Therefore,
groups B and C were combined for correlation with the
main outcome events. 
Clinical risk assessment by physicians participating in
the registry according to groups A and B/C will corre-
spond with other classifications, such as the ASA and
SVS/ISCVS-NA risk scores. Of a number of other factors,
the presence of diabetes, obesity, and advanced age corre-
lated with the clinical diagnosis of high risk (group B/C).
In addition, the presence of peripheral arterial occlusive
disease indicated with an ankle-brachial index of less than
0.87 also correlated with a diagnosis unfit for surgery or
anesthesia, a finding that confirmed a recently reported
observation by Powell et al.19
Patient selection appeared to be influenced by the
experience of the clinical team. A total experience of less
than 60 EAR procedures per surgical team was associated
with a significantly higher proportion of group C patients,
which suggests that these surgeons reserved EAR proce-
dures primarily for patients otherwise considered at high
risk for open aneurysm repair. This assumption is also sup-
ported by our observation that limited experience corre-
lated with a higher late mortality rate. It would seem to be
the case that more patients with better risk are accepted
for treatment as teams gain experience and overcome their
learning curves.
The mortality rate during the 1st month was signifi-
cantly higher in patients classified as having high operative
risk as compared with other patients. Variables in addition
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Fig 1. Distribution of factors taken into account in classifications of unfit for open surgery and unfit for anesthesia. In this
graph, main risk factor in each patient is represented.
to clinical assessment (groups A and B/C) that correlated
with increased perioperative mortality rates were ASA clas-
sification, age, and renal insufficiency. Notably, the factors
usually associated with an increased risk of death in rela-
tion to open aneurysmal repair, such as cardiac disease and
pulmonary disease, did not have an independent effect on
operative mortality rate in this series of patients with
endovascular treatment. It might be possible, though, that
in the multivariate model the effects of these factors were
already absorbed by the fit–unfit categorization. On the
other hand, it was observed previously that EAR is associ-
ated with less challenge of the respiratory system and
decreased cardiac stress.20,21
The reported series of patients with untreated AAAs in
which rupture rates were studied invariably involve rela-
tively small numbers. The earliest observed series of 127
patients with untreated AAAs of more than 5 cm was
reported by Szilagyi, Elliott, and Smith.1 That study
emphasized the relation between the risk of rupture and
the size of the aneurysm. In patients with aneurysms larger
than 6.0 cm, 42% of the deaths were caused by rupture,
and in smaller aneurysms, this figure was 36%. We have
investigated the effect of EAR on mortality rate with the
intrapolation in our current life table data of patients with
unfit conditions of a rupture rate of 0.11 (incidence rate
of rupture per person-year) documented in untreated
aneurysms between 5.0 and 6.0 cm.13 There was an
appreciable benefit in terms of survival rate resulting from
minimization of the risk of rupture with endovascular
aneurysm exclusion, with this rupture rate for comparison.
The advantage of EAR became apparent after approxi-
mately 1 year. Thus, the life expectancy of patients at high
risk who opt for EAR should be longer than 1 year before
any realistic gain in life span can be anticipated.
The risk of rupture varies with the size of the
aneurysm, being minimal in aneurysms with a diameter
less than 5 cm, becoming clinically significant in untreated
aneurysms of 5.0 to 5.9 cm, and increasing dramatically in
aneurysms with diameters more than 6.0 cm.1,2,13,18,22,23
In recognition of this relationship, some authors advocate
operative treatment only in those patients with AAAs
larger than 6.0 cm.24 There may be justification for a
lower threshold diameter for intervention in patients with
conditions that are suitable for EAR. From this analysis, it
is apparent that in patients who undergo EAR (in which
group the rate of rupture was low) the nonrupture death
rate was significantly higher in patients with aneurysms 6.0
or more as compared with patients with smaller
aneurysms. This pattern was similar for patients at normal
and high operative risk. Thus, aneurysm size appeared to
correlate strongly with the probability of both late death
related to the aneurysm and death from comorbidity. The
benefits from EAR appeared comparable in patients with
aneurysms less than 6 cm and in those patients with
aneurysms 6 cm or more in diameter, as the proportion of
death from rupture relative to death from all causes after
2 years was 44% and 43% for aneurysms less than 6 cm and
6 cm or more, respectively. When these data are taken in
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account, it may be argued that the optimal threshold for
endovascular interventions is definitely less than 6.0 cm.
The data suggest that endovascular repair is justifiable in
aneurysms larger than 5 cm, provided the patient is
expected to survive for more than 1 year. These findings
are in agreement with conclusions drawn previously from
a predictive model reported by Finlayson et al.3 These
authors recommended lowering the size threshold for
interventional treatment of aneurysms suitable for EAR to
less than 6 cm, which was hitherto the conventionally
accepted threshold for open AAA repair in patients at high
risk.24 Finlayson et al3 observed also that the greatest
potential impact of EAR was in patients at high risk.
This study has several limitations. First, a prospective
registry is not a rigorously monitored study, and the assess-
ment of preoperative factors and determination of the indi-
cations for EAR are undertaken independently by a large
number of institutions and physicians with inevitable vari-
ability. A small number of patients in the group with con-
ditions identified as unfit for surgery had AAAs smaller
than 5 cm, which would obviate the need for any inter-
vention. However, in review of the details of this category,
it appeared that most of these aneurysms were between 4.5
and 5.0 cm, and additional indications, such as rapid
growth, a saccular configuration, or large iliac aneurysms,
although not reported, may have been present. Secondly,
one third of the patients classified in group C still under-
went general anesthesia. This seemingly erroneous patient
grouping can be explained by the fact that exploration of
Fig 2. Survival curves in patients at normal operative risk (group
A), in patients with conditions unfit for open surgery (group B),
and in patients with conditions unfit for anesthesia (group C).
*Deaths during the first postoperative month.
the femoral artery and catheter intervention requires a
lighter anesthesia than does a major abdominal procedure.
Thirdly, assessment of clinical risk according to groups A,
B, and C was largely subjective rather than a formal scor-
ing system. Although this is the same principle that was
used to exclude patients from AAA repair before endo-
vascular treatment was an option,1,2,18,25 a system with
standardized objective parameters may be preferable. POS-
SUM (Physiologic and Operative Severity Score for
enUmeration of Mortality and morbidity) scoring system is
a proven method for the estimation of the risk of death or
complications in individuals after major surgery, and this
system has been adapted successfully for vascular surgical
procedures.26 The system is quantitative and was found to
correlate well with postoperative mortality after aneurysm
surgery. This system may become applicable to studies of
the type described here, although some additional modifi-
cations may be necessary for endovascular interventions.27
The POSSUM predictor equation or other predicting rules
may well be useful in future auditing projects of EAR 
procedures.26,28 Fourthly, we assumed in the theoretic
model of patients who did not undergo treatment that 
all aneurysm ruptures occurring during the follow-up
period would result in death and disregarded the option 
of emergency surgery. This assumption may seem reason-
able because the overall fatality rate after AAA rupture
(including patients at normal risk) is reported to be 
80% to 90%.29,30 The chance of aneurysm rupture survival 
by patients with conditions previously declared unfit 
for open repair indeed seems almost negligible. Finally, 
the mathematic model we used to estimate the relative 
gain in survival rate after EAR was on the basis of the
presently observed outcome during follow-up examination
and of rupture rates derived from reports on the natural
history of aneurysms. The reported annual risk of rupture
varies between 0.03 and 0.14 in AAAs of 5 to 5.9
cm.13,22,23,25,31,32 In this size range, we investigated a rate
of 0.11, which appeared in accordance with life table data
of patients with untreated AAAs, published in two large
recent studies.2,18 It was not methodologically sound to use
the mathematic model for the assessment of the statistical
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Fig 3. Observed survival rate curve in patients with unfit condi-
tions who underwent endovascular abdominal aortic aneurysm
repair (EAR; group B/C) and in theoretically similar cohort of
patients with untreated abdominal aortic aneurysms and assumed
annual rupture rate of 0.11. *Deaths during the first postopera-
tive month.
Fig 4. Survival rate curves in patients with unfit conditions who
underwent endovascular abdominal aortic aneurysm repair
(EAR; group B/C) and in theoretically similar group of patients
without treatment of abdominal aortic aneurysm (AAA) in (a)
patients with AAAs less than 6.0 cm and in (b) patients with AAAs
6.0 cm or more. *Deaths during the first postoperative month.
A
B
significance of calculated differences in mortality rates
between patients with EAR and no intervention.
CONCLUSION
Early and late mortality rates after EAR were increased
in patients at high risk for open surgery as compared with
patients at normal risk. Subjective clinical assessment of
risk correlated as well or better with early and late survival
rates than scored classifications. However, there is a need
to develop better standardized systems for the prediction
of outcome after EAR. Our estimate that endovascular
repair will offer a significant reduction in all cause death
rates in patients at high risk with AAAs beyond 1 year after
operation requires confirmation by a prospective random-
ized trial that compares EAR with a conservative treat-
ment in this category of patients.
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Dr Frank J. Veith (Bronx, NY). I rise to question your
assumption that aneurysms that are untreated, even if they are
over 5 cm, have an 11% to 14% rupture rate within whatever
period of time you claimed they had it. We have recently made the
point that not all large aneurysms, that is, over 5.5 cm, need to
be treated either openly or endovascularly, particularly if they are
very unfavorable for an endovascular approach.
And we base that on a series of 72 patients presented at the
Eastern Vascular Society that were followed from 6 to 72 months
without operative treatment. In that group of patients, when the
aneurysms enlarged or became symptomatic, 53 of them ulti-
mately underwent a repair with an 11% mortality. In addition, of
the entire group, 19 not requiring any repair at all and 53 requir-
ing repair, there was only a 4% mortality from rupture with this
conservative treatment. So, we question the premise that all large
aneurysms, that is, over 5.5 cm, need to be treated, particularly
when their anatomy is unfavorable for endovascular repair and
they are at very high risk for open repair.
I would ask you the question: did you look at the unfit group
that had endovascular treatment to see if they had a very high
incidence of unfavorable factors that might have caused the high
mortality that you observed in that group?
Dr Jacob Buth. Thank you very much, Dr Veith. These were
good questions, as they bring up the matter of what is the appro-
priate comparative group with conservative treatment? The rupture
rates that we used in this analysis were derived from the literature.
The available reports are on the fate of patients during a time that
endovascular repair was not an option. The choice was between no
treatment or open surgical treatment. It might well be that these
comparisons differ from a comparison in the more recent period,
where endovascular treatment is the alternative for no treatment. If
one would analyze outcome in a group at high risk with unfavor-
able anatomy not eligible for EAR, rupture rates may differ from
previously described series wtih a conservative approach. However,
the main risk factors for rupture will remain: size of the aneurysm,
age of the patient (high age corresponds with more deaths from
nonaneurysmal causes), and perhaps female gender.
One may conclude that new studies comparing risk of rup-
ture and death from comorbidities in EAR and conservatively
treated patients need to be performed.
Dr Roy Greenberg (Cleveland, Ohio). I again enjoyed your
paper and always value the input of the EUROSTAR Registry
because of the numbers that you have. My question relates to the
fact that your conclusions include the fact that one of the acute
benefits for all endovascular repairs was a fairly low morbidity and
mortality. However, the incidence of device-related, more than
30-day complications were high in the endovascular group. Is
there a trend over time demonstrating that our ability to treat
these patients has improved, or has this been a fairly steady thing
where we have seen a stable rate of 5% 30-day mortality?
Dr Buth. Thank you for your question, Dr Greenberg. We
have made an adjustment for the year in which the patients were
treated. In this analysis, we have left out a cohort of approxi-
mately 600 patients that were retrospectively enrolled in the
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Appendix. Participants of 101 institutions that contributed data to this EUROSTAR study
Austria: Vienna: Prof G. Kretschmer.
Belgium: Bonheiden: Dr P.M.A.J. Peeters; Bruxelles: Dr R. Verhelst; Gilly: Dr H. Massin; Leuven: Prof A. Nevelsteen; St Truiden:
Dr F. van Elst; Turnhout: Dr P. Stabel; Wilrijk/Antwerpen: Dr M. van Betsbrugge.
France: Draguignan: Dr C. Mialhe; Grenoble: Dr Magne; Lille cedex: Dr M.A. Vasseur; Lyon: Dr B. Age; Marseille: Dr Piquet;
Montpellier: Prof Marty-Ane; Nancy: Dr C. Amicabile; Nanterre: Dr J. Marzella; Nimes: Dr Cardon; Paris cedex: Prof J.C. Gaux;
Paris Creteil Cedex: Prof J.P. Becquemin; St Etienne: Prof J.P. Favre; St Laurant du Var: Prof P. Kreitmann; Toulouse: Prof H.
Rousseau; Toulouse Cedex: Dr C. Giraud.
Germany: Bonn: Dr A. Viehofer; Dusseldorf: Dr R. Kolvenbach; Frankfurt: Prof W. Stelter; Frankfurt: Prof H. Sievert; Freiburg: Dr
Uhrmeister; Hamburg: Prof H. Kortmann; Hanover: Dr G. Voshage; Kempten: Dr Antoni; Koblenz: Dr R. Wickenhoefer; Mainz: Dr
C. Duber; Marburg: Prof M. Storck; Munchen: Prof P.C. Maurer; Oldenburg: Dr Ratusinski; Ulm: Dr Pamler.
Greece: Psihico Athens: Prof P. Balas.
Ireland: Dublin: Dr S. Sultan.
Israel: Tel Aviv: Prof B. Morach.
Italy: Perugia: Prof P. Cao; Roma: Dr M. Scoccianti.
Luxembourg: Luxembourg: Dr P. Berg.
Monaco: Monaco: Dr C. Mialhe.
The Netherlands: Alkmaar: Dr H. van Dijk; Amsterdam: Dr R. Balm; Amsterdam: Dr A. Vahl; Amsterdam: Dr W. Wisselink;
Arnhem: Dr W.R. de Vries; Delft: Dr J. Koning; Den Haag: Dr J.C.A. de Mol van Otterloo; Den Haag: Dr H. van Overhagen;
Dordrecht: Dr R.P. Tutein Nolthenius; Eindhoven: Dr J. Buth; Enschede: Dr R.H. Geelkerken; Groningen: Dr H.R. Dop;
Groningen: Dr E. Verhoeven; Leiden: Prof J.H. van Bockel; Maastricht: Dr G.W.H. Schurink; Nieuwegein: Dr F. Moll; Nijmegen: Dr
W.B. Barendrecht; Nijmegen: Prof J. van Vliet; Rotterdam: Dr A.C. van der Ham; Rotterdam: Dr van Sambeek; Rotterdam: Dr A. de
Smet; Tilburg: Dr J.F. Hamming; Tilburg: Dr S. Kranendonk; Utrecht: Dr J. Blankensteijn; Veldhoven: Dr J.A. Charbon; Zwolle: Dr
P. Jörning.
Norway: Oslo: Prof A. Kroeze; Oslo: Dr K. Krohg-Soerensen; Trondheim: Prof H. Myhre.
Poland: Lublin: Prof Michalak.
Spain: Barcelona: Dr M. Cairols; Barcelona: Dr J. Escudero Rodriguez; Barcelona: Dr V. Riambau; Donostia San Sebastian: Dr M. de
Blas; Leon: Dr R. Fernandez-Samos Gutierrez; Lugo: Dr J.R. Pulpeiro; Madrid: Dr F. Acin; Madrid: Dr E. Criado; Madrid: Dr
Sanchez-Corral; Madrid: Dr D. Tagarro; Madrid: Dr J. Urbano; Pamplona: Dr L. Fernandez Alonso; Valladolid: Dr C. Vaquero-
Puerta.
Sweden: Lund: Prof L. Norgren; Orebro: Dr Th. Nordh Larzon; Stockholm: Prof J. Swedenborg.
Switzerland: Bern: Dr J. Schmidli; Zurich: Dr M. Enzler.
United Kingdom: Bournemouth: Dr S. Darke; Bristol: Dr R. Baird; Chester: Dr G. Abbott; Glasgow: Dr R. Edwards; Hull: Dr D.
Ettler; Liverpool: Dr P. Harris; London: Dr J. Wolfe; Manchester: Dr R. Asleigh; New Castle-Upon-Tyne: Dr M.G. Wyatt.
EUROSTAR Registry. So, we only have taken the prospectively
enrolled patients into account. In the multivariate analysis, the
year of operation was not a significant variable. Thus, the answer
is that the 1st month mortality remains fairly constant over the
years of the study in both the unfit and in the normal risk groups.
The operative mortality was significantly higher in unfit patients
treated early and late during the study.
Dr Alun H. Davies (London, United Kingdom). I would just
like to ask you the question about the difference between the ASA
classification and your fitness for general anesthesia. Because we all
know that when it is a physician decision as to whether somebody
is fit for anesthesia, there is a lot of variation. And one of the prob-
lems with the EUROSTAR data is that it has very much been left
to the individual investigators. So, do you really feel that your
claims are justified when there is not a fixed protocol for the actual
determination of fit and unfit? Because the other question must
be, if you have not found a relationship with respect to the ASA
classification, there must be some degree of variability.
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Dr Buth Mr Davies, preoperative risk scoring is a subject in
which there is little consensus. The ASA score is a commonly used
system today. However, this is a broad indicator, although we
found a significant correlation with clinical assessment by the par-
ticipants in the registry. In the literature, clinical estimate of high
operative risk was the most commonly used method in articles
studying outcome of conservatively treated patients with large-
size aneurysms. This was also the case in a number of studies per-
formed in the UK.2,18
I am aware of the fact that the POSSUM score is, at the pres-
ent time, quite popular in England. However, this initially was
not a practical preoperative risk score as it required findings made
by open surgery to fit into the equation. To my knowledge, there
is as yet no validated modification of the POSSUM score for
endovascular treatment of aneurysms. Your question, why no uni-
form validated scoring method was used for assessment of opera-
tive risk, is quite justified. The answer is: there was none during
the time of our study as far as I know.
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